Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies.
about
Allopurinol: insights from studies of dose-response relationships.Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment optionsTailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Nephrolithiasis as a Risk Factor for CKD: The Atherosclerosis Risk in Communities Study.Investigational drugs for hyperuricemia.Management of Gout and Hyperuricemia in CKD.Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study.Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor.Cardiac and renal protective effects of urate-lowering therapy.An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout.Combining Hyperechoic Aggregates and the Double-Contour Sign Increases the Sensitivity of Sonography for Detection of Monosodium Urate Deposits in Gout.The British Society for Rheumatology Guideline for the Management of Gout.Frequency and associations of chronic kidney disease among gout patients from a University Teaching Hospital in Nigeria.Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy.
P2860
Q30240163-0A67800E-3A8D-4968-8A72-9E6A55F740D3Q33864537-63C672A7-4882-4268-A1AF-B8072F2976B4Q34557668-0930CF77-9841-4818-AD8A-E1F0285BF15AQ36250333-EEBEAC5E-EE7B-4656-8421-A785107509ABQ38527441-E008EF87-9747-4AB4-B421-F3CABAD668C7Q38812962-6576CB6C-5B6F-4B53-9EAF-146CB6B1F077Q39687173-640888F3-7B21-4627-9FD7-6E203BD76DD1Q40110480-2B896790-F356-4E45-AEC6-5AC527ED17C5Q47150749-AE1695E5-E156-4164-AAEE-A61494459B17Q49616077-BEAB31B5-11DA-4900-AACD-8C78C46F8932Q51746453-892D6FAB-5E28-4346-BA95-A47DB228F2C1Q53726829-6ED07557-41F8-4E87-B893-266090B04044Q55060116-C9BA4918-6085-44E2-8F9A-5E75974EEF56Q55093441-0214B862-58FB-4BCF-BAC0-7937776B5B98Q55284599-D601E640-54F1-4CF1-BA23-92547A91DD55Q55346305-7ECF68C8-5028-4DE8-AAFA-BC81ED5748DF
P2860
Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Gout and risk of chronic kidne ...... ysis of observational studies.
@ast
Gout and risk of chronic kidne ...... ysis of observational studies.
@en
type
label
Gout and risk of chronic kidne ...... ysis of observational studies.
@ast
Gout and risk of chronic kidne ...... ysis of observational studies.
@en
prefLabel
Gout and risk of chronic kidne ...... ysis of observational studies.
@ast
Gout and risk of chronic kidne ...... ysis of observational studies.
@en
P2093
P2860
P31
P921
P1476
Gout and risk of chronic kidne ...... ysis of observational studies.
@en
P2093
Christian D Mallen
Edward Roddy
John Belcher
P2860
P2888
P356
10.1186/S13075-015-0610-9
P5008
P577
2015-04-01T00:00:00Z
P6179
1044346783